Company: SUPN
Filing Date: 2025-02-24
Form Type: 8-K
Source: 0001356576-25-000011
Chunk: 0

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-24
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

of Certain Officers.

(e) Modification of Compensatory Arrangements with Executive Officers

On February 19, 2025, the Compensation Committee (the “ Committee”) of Supernus Pharmaceuticals, Inc. (“ Supernus” or the “ Company”) recommended, and the Board of Directors (the “ Board”) approved, modifications of the compensation of the Company’s executive officers other than the Chief Executive Officer, as follows:

The annual base salary of Timothy C. Dec, the Company’s Senior Vice President and Chief Financial Officer, was increased from $485,500 to $504,900. Mr. Dec was awarded a 2024 bonus of $229,160, and was granted options to purchase 40,000 shares of common stock, 4,500 restricted stock units (RSUs), and 5,000 performance share units (PSUs), which will vest depending upon the level of achievement of specified performance goals. In addition, Mr. Dec’s bonus target for 2025 is unchanged from 2024 and is 45% of his base salary.

The annual base salary of Padmanabh P. Bhatt, Ph. D., the Company’s Senior Vice President, Intellectual Property and Chief Scientific Officer, was increased from $440,500 to $455,900. Dr. Bhatt was awarded a 2024 bonus of $163,434 and was granted options to purchase 20,000 shares of common stock, 4,500 RSUs and 5,000 PSUs, which will vest depending upon the level of achievement of specified performance goals. Dr. Bhatt’s bonus target for 2025 is unchanged from 2024 and is 35% of his base salary.

The annual base salary of Jonathan Rubin, M. D., the Company’s Senior Vice President and Chief Medical Officer, was increased from $466,400 to $485,100. Dr. Rubin was awarded a 2024 bonus of $192,530 and was granted options to purchase 20,000 shares of common stock, 4,500 RSUs and 5,000 PSUs, which will vest depending upon the level of achievement of specified performance goals. Dr. Rubin’s bonus target for 2025 is unchanged from 2024 and is 40% of his base salary.

The annual base salary of Frank Mottola, the Company’s Senior Vice President